Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 27

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Guttate psoriasis

Recruiting

Study on Early Treatment of Plaque Psoriasis with Bimekizumab and Clobetasol Propionate for Patients with Chronic Inflammation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Bimekizumab
  • Sponsor:Centre Hospitalier Universitaire De Nice

Rheumatoid arthritis

Recruiting

Study on [18F]Fluoro-PEG-Folate PET-CT Imaging to Monitor Therapy Response in Patients with Rheumatoid Arthritis

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Amsterdam UMC Stichting

Aortic valve stenosis+2

Recruiting

Study of Colchicine Treatment to Slow Down Aortic Valve Stenosis Progression in Adult Patients with Moderate Disease

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Stichting Radboud University Medical Center

Axial spondyloarthritis

Recruiting

Study Comparing Infliximab and NSAID Drug Combination for Patients with Axial Spondyloarthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acemetacin
  • Sponsor:St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr

Scleroderma associated digital ulcer

Recruiting

Study on the Safety of TOP-N53 for Treating Digital Ulcers in Systemic Sclerosis Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sildenafil Citrate
  • Sponsor:Topadur Pharma AG

Neonatal alloimmune thrombocytopenia

Recruiting

Study of Nipocalimab or IVIG for Pregnant Women at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Type 1 diabetes mellitus+1

Recruiting

Study on Lisdexamfetamine and Methylphenidate for Children with ADHD and Type 1 Diabetes

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Lisdexamfetamine Dimesylate
  • Sponsor:Medical University Of Lodz

Systemic lupus erythematosus

Recruiting

Study on the Effects of Rituximab and Obinutuzumab in Patients with Systemic Lupus Erythematosus (SLE)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Amsterdam UMC Stichting

Inflammatory bowel disease+1

Recruiting

Study on the Safety of Faster Infusions for Cancer Patients Using Trastuzumab, Bevacizumab, and Atezolizumab

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Isala Klinieken Stichting

Systemic lupus erythematosus

Recruiting

Study on the Effects of Belimumab for Patients with Systemic Lupus Erythematosus (SLE)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Amsterdam UMC Stichting

Neuromyelitis optica spectrum disorder

Recruiting

Study of Satralizumab for Children with Neuromyelitis Optica Spectrum Disorder (NMOSD)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Satralizumab
  • Sponsor:F. Hoffmann-La Roche AG

Hereditary angioedema

Recruiting

Long-Term Safety Study of Berotralstat for Patients with Hereditary Angioedema from Previous Trials

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Berotralstat
  • Sponsor:Biocryst Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.